{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T07:22:20Z","timestamp":1765610540911,"version":"3.37.3"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"U.S. NIH grants","award":["R01GM121600"],"award-info":[{"award-number":["R01GM121600"]}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["#178382"],"award-info":[{"award-number":["#178382"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP23fk0310513"],"award-info":[{"award-number":["JP23fk0310513"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-83104-0","type":"journal-article","created":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T20:13:59Z","timestamp":1735589639000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Theoretical modeling of hepatitis C acute infection in liver-humanized mice support pre-clinical assessment of candidate viruses for controlled-human-infection studies"],"prefix":"10.1038","volume":"14","author":[{"given":"Zhenzhen","family":"Shi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adquate","family":"Mhlanga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ari","family":"Josephson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholson T.","family":"Collier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromi","family":"Abe-Chayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chise","family":"Tateno-Mukaidani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott J.","family":"Cotler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Ozik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marian","family":"Major","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordan J.","family":"Feld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuaki","family":"Chayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harel","family":"Dahari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,30]]},"reference":[{"key":"83104_CR1","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/S0140-6736(23)01320-X","volume":"402","author":"M Martinello","year":"2023","unstructured":"Martinello, M. et al. Hepatitis C. Lancet 402, 1085\u20131096 (2023).","journal-title":"Lancet"},{"key":"83104_CR2","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1053\/j.gastro.2009.09.017","volume":"138","author":"WO Osburn","year":"2010","unstructured":"Osburn, W. O. et al. Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology 138, 315\u2013324 (2010).","journal-title":"Gastroenterology"},{"key":"83104_CR3","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1053\/j.gastro.2010.05.077","volume":"139","author":"H Dahari","year":"2010","unstructured":"Dahari, H., Feinstone, S. M. & Major, M. E. Meta-analysis of hepatitis C virus vaccine efficacy in chimpanzees indicates an importance for structural proteins. Gastroenterology 139, 965\u2013974 (2010).","journal-title":"Gastroenterology"},{"key":"83104_CR4","doi-asserted-by":"crossref","unstructured":"Wester, C. Hepatitis C virus clearance cascade\u2014United, S. 2013\u20132022. Morbidity and Mortality Weekly Report 72 (2023).","DOI":"10.15585\/mmwr.mm7226a3"},{"key":"83104_CR5","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1056\/NEJMoa2023345","volume":"384","author":"K Page","year":"2021","unstructured":"Page, K. et al. Randomized trial of a vaccine regimen to prevent chronic HCV infection. N. Engl. J. Med. 384, 541\u2013549 (2021).","journal-title":"N. Engl. J. Med."},{"key":"83104_CR6","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1056\/NEJMsb2109093","volume":"385","author":"TJ Liang","year":"2021","unstructured":"Liang, T. J. et al. Controlled human infection model-fast track to HCV vaccine? N. Engl. J. Med. 385, 1235\u20131240 (2021).","journal-title":"N. Engl. J. Med."},{"key":"83104_CR7","doi-asserted-by":"publisher","first-page":"S262","DOI":"10.1093\/cid\/ciad362","volume":"77","author":"JJ Feld","year":"2023","unstructured":"Feld, J. J. et al. Controlled human infection model for hepatitis C virus vaccine development: trial design considerations. Clin. Infect. Dis. 77, S262\u2013S269 (2023).","journal-title":"Clin. Infect. Dis."},{"key":"83104_CR8","doi-asserted-by":"publisher","first-page":"e0210173","DOI":"10.1371\/journal.pone.0210173","volume":"14","author":"E Shteyer","year":"2019","unstructured":"Shteyer, E. et al. Modeling suggests that microliter volumes of contaminated blood caused an outbreak of hepatitis C during computerized tomography. Plos one. 14, e0210173 (2019).","journal-title":"Plos one"},{"key":"83104_CR9","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1053\/j.gastro.2005.01.049","volume":"128","author":"H Dahari","year":"2005","unstructured":"Dahari, H. et al. Mathematical modeling of primary hepatitis C infection: noncytolytic clearance and early blockage of virion production. Gastroenterology 128, 1056\u20131066 (2005).","journal-title":"Gastroenterology"},{"key":"83104_CR10","unstructured":"Collins, F. S. NIH Will No Longer Support Biomedical Research on Chimpanzees (National Institutes of Health, 2015)."},{"key":"83104_CR11","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1111\/jvh.12551","volume":"23","author":"S DebRoy","year":"2016","unstructured":"DebRoy, S. et al. Hepatitis C virus dynamics and cellular gene expression in uPA-SCID chimeric mice with humanized livers during intravenous silibinin monotherapy. J. Viral Hepat. 23, 708\u2013717 (2016).","journal-title":"J. Viral Hepat."},{"key":"83104_CR12","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1136\/gutjnl-2012-302600","volume":"62","author":"N Shi","year":"2013","unstructured":"Shi, N. et al. Combination therapies with NS5A, NS3 and NS5B inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric mice. Gut 62, 1055\u20131061 (2013).","journal-title":"Gut"},{"key":"83104_CR13","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1099\/jgv.0.001268","volume":"100","author":"M Osawa","year":"2019","unstructured":"Osawa, M. et al. Efficacy of glecaprevir and pibrentasvir treatment for genotype 1b hepatitis C virus drug resistance-associated variants in humanized mice. J. Gen. Virol. 100, 1123\u20131131 (2019).","journal-title":"J. Gen. Virol."},{"key":"83104_CR14","doi-asserted-by":"publisher","first-page":"S257","DOI":"10.1093\/cid\/ciad336","volume":"77","author":"TJ Liang","year":"2023","unstructured":"Liang, T. J. et al. Challenge inoculum for hepatitis C virus controlled human infection model. Clin. Infect. Dis. 77, S257\u2013S261 (2023).","journal-title":"Clin. Infect. Dis."},{"key":"83104_CR15","doi-asserted-by":"publisher","first-page":"e1011309","DOI":"10.1371\/journal.pcbi.1011309","volume":"19","author":"A Hailegiorgis","year":"2023","unstructured":"Hailegiorgis, A. et al. Modeling suggests that virion production cycles within individual cells is key to understanding acute hepatitis B virus infection kinetics. PLoS Comput. Biol. 19, e1011309 (2023).","journal-title":"PLoS Comput. Biol."},{"key":"83104_CR16","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1002\/hep.29891","volume":"68","author":"Y Ishida","year":"2018","unstructured":"Ishida, Y. et al. Acute hepatitis B virus infection in humanized chimeric mice has multiphasic viral kinetics. Hepatology 68, 473\u2013484 (2018).","journal-title":"Hepatology"},{"key":"83104_CR17","doi-asserted-by":"publisher","first-page":"e0142145","DOI":"10.1371\/journal.pone.0142145","volume":"10","author":"C Tateno","year":"2015","unstructured":"Tateno, C. et al. Generation of novel chimeric mice with humanized livers by using hemizygous cDNA-uPA\/SCID mice. PloS one. 10, e0142145 (2015).","journal-title":"PloS one"},{"key":"83104_CR18","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.bbrc.2006.05.085","volume":"346","author":"T Umehara","year":"2006","unstructured":"Umehara, T. et al. Serine palmitoyltransferase inhibitor suppresses HCV replication in a mouse model. Biochem. Biophys. Res. Commun. 346, 67\u201373 (2006).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"83104_CR19","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s42826-022-00150-3","volume":"38","author":"S Ahmadi-Noorbakhsh","year":"2022","unstructured":"Ahmadi-Noorbakhsh, S. et al. Anesthesia and analgesia for common research models of adult mice. Lab. Anim. Res. 38, 40 (2022).","journal-title":"Lab. Anim. Res."},{"key":"83104_CR20","doi-asserted-by":"publisher","first-page":"e0049220","DOI":"10.1128\/JVI.00492-20","volume":"95","author":"V Reinharz","year":"2021","unstructured":"Reinharz, V. et al. Understanding hepatitis B virus dynamics and the antiviral effect of interferon alpha treatment in humanized chimeric mice. J. Virol. 95, e0049220 (2021).","journal-title":"J. Virol."},{"key":"83104_CR21","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1053\/j.gastro.2009.04.048","volume":"137","author":"T Matsumura","year":"2009","unstructured":"Matsumura, T. et al. Amphipathic DNA polymers inhibit hepatitis C virus infection by blocking viral entry. Gastroenterology 137, 673\u2013681 (2009).","journal-title":"Gastroenterology"},{"key":"83104_CR22","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1126\/science.1114016","volume":"309","author":"BD Lindenbach","year":"2005","unstructured":"Lindenbach, B. D. et al. Complete replication of hepatitis C virus in cell culture. Science 309, 623\u2013626 (2005).","journal-title":"Science"},{"key":"83104_CR23","first-page":"2171","volume":"13","author":"F-A Fortin","year":"2012","unstructured":"Fortin, F-A. et al. DEAP: Evolutionary algorithms made easy. J. Mach. Learn. Res. 13, 2171\u20132175 (2012).","journal-title":"J. Mach. Learn. Res."},{"key":"83104_CR24","doi-asserted-by":"crossref","unstructured":"B\u00e4ck, T., Fogel, D. & Michalewicz, Z. Evolutionary Computation (Institute of Physics Publishing, 2000).","DOI":"10.1201\/9781420034349"},{"key":"83104_CR25","doi-asserted-by":"crossref","unstructured":"Ozik, J. et al. From desktop to large-scale model exploration with Swift\/T, in WSC (IEEE, 2016).","DOI":"10.1109\/WSC.2016.7822090"},{"key":"83104_CR26","doi-asserted-by":"publisher","first-page":"11082","DOI":"10.1128\/JVI.01307-06","volume":"80","author":"J Zhong","year":"2006","unstructured":"Zhong, J. et al. Persistent hepatitis C virus infection in vitro: coevolution of virus and host. J. Virol. 80, 11082\u201311093 (2006).","journal-title":"J. Virol."},{"key":"83104_CR27","doi-asserted-by":"publisher","first-page":"e65297","DOI":"10.7554\/eLife.65297","volume":"10","author":"L Shekhtman","year":"2021","unstructured":"Shekhtman, L. et al. Modeling hepatitis C virus kinetics during liver transplantation reveals the role of the liver in virus clearance. Elife 10, e65297 (2021).","journal-title":"Elife"},{"key":"83104_CR28","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1002\/hep.20239","volume":"39","author":"ME Major","year":"2004","unstructured":"Major, M. E. et al. Hepatitis C virus kinetics and host responses associated with disease and outcome of infection in chimpanzees. Hepatology 39, 1709\u20131720 (2004).","journal-title":"Hepatology"},{"key":"83104_CR29","doi-asserted-by":"publisher","first-page":"6586","DOI":"10.1128\/JVI.76.13.6586-6595.2002","volume":"76","author":"ME Major","year":"2002","unstructured":"Major, M. E. et al. Previously infected and recovered chimpanzees exhibit rapid responses that control hepatitis C virus replication upon rechallenge. J. Virol. 76, 6586\u20136595 (2002).","journal-title":"J. Virol."},{"key":"83104_CR30","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/S2468-1253(20)30081-9","volume":"5","author":"JJ Feld","year":"2020","unstructured":"Feld, J. J. et al. Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-centre, open-label study. Lancet Gastroenterol. Hepatol. 5, 649\u2013657 (2020).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"83104_CR31","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1126\/science.277.5325.570","volume":"277","author":"AA Kolykhalov","year":"1997","unstructured":"Kolykhalov, A. A. et al. Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. Science 277, 570\u2013574 (1997).","journal-title":"Science"},{"key":"83104_CR32","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1002\/hep.32632","volume":"77","author":"E Barnes","year":"2023","unstructured":"Barnes, E. et al. Implementation of a controlled human infection model for evaluation of HCV vaccine candidates. Hepatology 77, 1757\u20131772 (2023).","journal-title":"Hepatology"},{"key":"83104_CR33","doi-asserted-by":"publisher","first-page":"S270","DOI":"10.1093\/cid\/ciad359","volume":"77","author":"NH Shoukry","year":"2023","unstructured":"Shoukry, N. H., Cox, A. L. & Walker, C. M. Immunological monitoring in hepatitis C virus controlled human infection model. Clin. Infect. Dis. 77, S270\u2013S275 (2023).","journal-title":"Clin. Infect. Dis."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-83104-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-83104-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-83104-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T21:07:33Z","timestamp":1735592853000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-83104-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,30]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["83104"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-83104-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2024,12,30]]},"assertion":[{"value":"23 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"YI and CTM are PhoenixBio employees. KC has received honoraria from Bristol-Myers Squibb and MSD K.K., AbbVie, Gilead Science, Dainippon Sumitomo Pharma and Mitsubishi Tanabe Pharma and research funding from Gilead Science, Dainippon Sumitomo Pharma, MSD K.K., AbbVie, Eisai, TORAY, Otsuka Pharma, Chugai Pharma, Takeda Pharma and Roche. JJF reports research funding and consulting fees from AbbVie and Gilead. All other authors have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"31826"}}